In Q1 2026, sales of fillers and biorevitalizants in Russia reached RUB 10.8 billion (at retail prices, including VAT), an increase of 35.5% compared to the same period in 2025. In physical terms, demand increased by 22.8% in minimum dosage units (MDU), to 1.71 million MDU or 1.1 million packages (+25.8%). This trend continues the results of record-breaking 2025, when over 12 months the market sold 6.34 million MDU (+10.4%) worth RUB 38.6 billion (+34.5%), achieving the highest monetary growth in the last three years.

In recent years, the Russian aesthetic medicine market in the filler and biorevitalizant segment has seen a qualitative shift in consumer demand and rapid growth in demand for high-tech multicomponent products in the premium price segment, against the backdrop of the washing out of budget category products. According to the database "Retail Audit of Injectable Cosmetic Product Sales in Russia (total sell out)" from the analytical company RNC Pharma, the share of injectable products costing less than RUB 5,000 decreased from 11.8% in 2022 to 7.8% in Q1 2026. The share of the RUB 5,000–10,000 segment also declined to 21.3%. At the same time, the dominant position in the market is occupied by products in the RUB 10,000–20,000 range per package, accounting for more than 49.3% of total retail value during the reporting period. The most dynamic growth was recorded in the premium price segment for products costing more than RUB 20,000, with their share nearly doubling over the past four years — from 12.3% in 2022 to 21.6% in the reporting period.

As an example of a successful premium hybrid cosmetic product, one can mention Yuvelook from the South Korean company Vime, which entered the domestic market in 2023. In the past year, sales volume of the product increased 80-fold in rubles compared to 2024. A striking example of import substitution and the transition to complex multicomponent formulations in the Russian market is the brand Biogel, developed at the Skolkovo Technopark. The product recently became available to consumers, yet in Q1 2026 it had already entered the top ten brands and captured nearly 4% of all ruble sales in the segment. Also notable was the 2023 market entry of the domestic drug Ellagen from Aptos. The manufacturer launched a collagen stimulator with a high (80%) concentration of polylactic acid (PLA). While the product still holds a small share of the overall market, it already accounts for more than 15% of monetary sales in the PLA product group.

In the past year, the market featured more than 1,300 SKUs of fillers and biorevitalizants, representing over 200 brands. In terms of monetary sales volume, the Belotero line from Merz Pharma retains the lead, accounting for 9.3% of the category's total monetary volume in Q1 2026. Compared to January–March 2025, the brand showed solid growth: +22% in rubles and +10% in packages.

Fig. Structure of the Russian Retail Market for Fillers and Biorevitalizants (including the clinical segment and specialized retail) by Price Segment in 2022–2025 and Q1 2026, % value